U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07169487) titled 'Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study' on Aug. 26.
Brief Summary: This Phase I, prospective, single-arm clinical study aims to evaluate the efficacy and safety of adjunctive methylene blue (MB) in patients experiencing cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) following CAR-T cell therapy or bispecific antibody treatment. Preclinical studies demonstrated that MB alleviates CRS/ICANS-related symptoms, preserves the antitumor function of T cells, and modulates neuroinflammation without compromising immune efficacy. The study will employ...